LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Testing Accuracy for Clostridium difficile Scrutinized

By LabMedica International staff writers
Posted on 31 Aug 2016
Print article
Image: The Mastercycler nexus thermal cycler (Photo courtesy of Eppendorf).
Image: The Mastercycler nexus thermal cycler (Photo courtesy of Eppendorf).
Accurate diagnosis of Clostridium difficile infection (CDI) is paramount for patient management and the wrong diagnosis places patients at risk, delays treatment, and/ or contributes to transmission of infection in the healthcare setting.

The selection of diagnostic tests to confirm CDI is controversial because of the variety of laboratory methods that are available and used across various facilities, and lack of standard recommendations for testing. Although amplification of the toxin B gene by polymerase chain reaction (PCR) is a sensitive method for detecting toxigenic C. difficile, false negative results still occur and could impact the diagnosis and treatment of this infection.

Scientists at the Northern Ontario School of Medicine (Sudbury, ON, Canada) and their colleagues tested stool samples from patients with diarrhea, and suspected of having CDI, were tested in the diagnostic laboratory for C. difficile using a PCR test and culture techniques. Multiplex PCR was performed on presumptive C. difficile isolates to detect the Toxin A gene (tcdA), Toxin B gene (tcdB), and the triose phosphate isomerase gene (tpi). The reactions were carried out in an Eppendorf Mastercycler nexus thermal cycler (Fisher Scientific, Ottawa, ON, Canada).

A total of 2,308 samples were tested for toxigenic C. difficile by GeneXpert C. difficile epi test (Cepheid, Sunnyvale, CA, USA) and culture methods over a 15-month period. The observed agreement of the results of the two tests was 95.1%. A total of 295 samples tested positive by GeneXpert, while 2,013 samples were negative by GeneXpert. C. difficile isolated from the discrepant samples resulted in diverse ribotyping patterns suggesting they were derived from different strains. The samples belonged to patients who were distributed evenly between age groups and wards in the hospital. In the majority of cases, the false negative C. difficile test results did not seem to impact the clinical outcome in these patients.

The authors concluded that although molecular methods are considered among the most sensitive methods available for clinical diagnosis of CDI, it seems inevitable that some cases, which are positive for C. difficile, might be missed when using this method, or any other method for that matter. Both clinical and analytical sensitivity of C. difficile tests should be considered when deciding which diagnostic assay to use, and clinical correlates should be examined carefully before excluding CDI as a cause of disease. The study was published on August 19, 2016, in the journal BMC Infectious Diseases.

Related Links:
Northern Ontario School of Medicine
Fisher Scientific
Cepheid
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more